Generic Name and Formulations:
Cefuroxime (as sodium) 750mg, 1.5g; IM or IV inj; sodium content 2.4mEq/g.
Indications for ZINACEF:
Susceptible bacterial septicemia, lower respiratory or urinary tract, skin and skin structure, meningitis, bone and joint infections, gonorrhea. Surgical prophylaxis.
Use IV route for serious infections. Usual duration of therapy: 5–10 days. Uncomplicated UTIs, skin and skin structure, disseminated gonorrhea, or uncomplicated pneumonia: 750mg every 8 hours. Severe or complicated infections, bone and joint: 1.5g every 8 hours; life-threatening: 1.5g every 6 hours; meningitis: max 3g every 8 hours. Uncomplicated gonorrhea: 1.5g IM once (divide into 2 injections) with 1g oral probenecid. Prophylaxis: see literature. Renal dysfunction: CrCl 10–20mL/min: 750mg every 12 hours; CrCl <10mL/min: 750mg every 24 hours. Coincide a dose for end of dialysis.
<3 months: not recommended. Give in equally divided doses. ≥3 months: usual range: 50–100mg/kg per day every 6–8 hours. Bone and joint: 150mg/kg per day every 8 hours. Meningitis: 200–240mg/kg per day IV every 6–8 hours. Renal dysfunction: reduce dose.
Penicillin allergy. Renal impairment, reduce dose. Monitor prothrombin time (in patients at risk), renal function. GI disease (esp. colitis). Elderly. Pregnancy (Cat.B). Nursing mothers.
Avoid aminoglycosides, furosemide, ethacrynic acid, other nephrotoxic drugs. May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Potentiated by probenecid.
Local reactions, blood dyscrasias, elevated liver enzymes; rarely: GI upset, rash (may be serious, eg, Stevens-Johnson syndrome), drug fever, anaphylaxis, interstitial nephritis, seizures, hearing loss in children treated for meningitis.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline